These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 22922573

  • 21. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA, Seibel WL, Kupert E, Hu XX, Potharla VY, Anderson MW.
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [Abstract] [Full Text] [Related]

  • 22. Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.
    Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL.
    Oncology; 2008 Jun; 74(3-4):188-97. PubMed ID: 18714167
    [Abstract] [Full Text] [Related]

  • 23. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y, Harada K, Ferdous T, Yoshida H.
    Anticancer Res; 2007 Jun; 27(4B):2365-75. PubMed ID: 17695527
    [Abstract] [Full Text] [Related]

  • 24. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
    Qiao X, Wang X, Shang Y, Li Y, Chen SZ.
    Cancer Commun (Lond); 2018 Jul 03; 38(1):43. PubMed ID: 29970185
    [Abstract] [Full Text] [Related]

  • 25. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.
    Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300
    [Abstract] [Full Text] [Related]

  • 26. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T, Endo S, Saito R, Hirose M, Hirai S, Suzuki H, Yamato K, Hyodo I.
    Oncol Res; 2013 Jun 01; 21(3):155-64. PubMed ID: 24512730
    [Abstract] [Full Text] [Related]

  • 27. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY, Lee BS, Chang JW, Park JK, Han JH, Kim YS, Shin YS, Byeon HK, Kim CH.
    Cancer Lett; 2016 Mar 01; 372(1):65-74. PubMed ID: 26721202
    [Abstract] [Full Text] [Related]

  • 28. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
    Pasello G, Urso L, Silic-Benussi M, Schiavon M, Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V, Favaretto A.
    J Thorac Oncol; 2014 Jul 01; 9(7):1008-1017. PubMed ID: 24922007
    [Abstract] [Full Text] [Related]

  • 29. Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells.
    Li L, Wen XZ, Bu ZD, Cheng XJ, Xing XF, Wang XH, Zhang LH, Guo T, Du H, Hu Y, Fan B, Ji JF.
    Oncol Rep; 2016 May 01; 35(5):3009-17. PubMed ID: 26986870
    [Abstract] [Full Text] [Related]

  • 30. Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo.
    Zhang C, Wu R, Zhu H, Hu YZ, Jiang H, Lin NM, He QJ, Yang B.
    Cancer Lett; 2011 Mar 01; 302(1):11-9. PubMed ID: 21236562
    [Abstract] [Full Text] [Related]

  • 31. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, Fulda S.
    Cancer Res; 2008 Oct 01; 68(19):7956-65. PubMed ID: 18829553
    [Abstract] [Full Text] [Related]

  • 32. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL.
    Clin Cancer Res; 2008 May 15; 14(10):3168-76. PubMed ID: 18483385
    [Abstract] [Full Text] [Related]

  • 33. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A, Kawakubo T, Nakamura S, Yamamoto K.
    Biol Chem; 2010 Aug 15; 391(8):947-58. PubMed ID: 20482316
    [Abstract] [Full Text] [Related]

  • 34. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.
    Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H.
    Cancer Res; 2010 Feb 01; 70(3):1101-10. PubMed ID: 20103630
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 37. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC.
    Gastroenterology; 2011 Aug 15; 141(2):663-73. PubMed ID: 21683075
    [Abstract] [Full Text] [Related]

  • 38. The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells.
    Zhu H, Huang M, Ren D, He J, Zhao F, Yi C, Huang Y.
    Biomed Res Int; 2013 Aug 15; 2013():293874. PubMed ID: 24324958
    [Abstract] [Full Text] [Related]

  • 39. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K, Fang W, Chen Y, Lin S, Chen X.
    Oncol Rep; 2014 Sep 15; 32(3):1234-42. PubMed ID: 25017445
    [Abstract] [Full Text] [Related]

  • 40. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.
    LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.
    Nat Med; 2002 Mar 15; 8(3):274-81. PubMed ID: 11875499
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.